BR112019024538A2 - composição para uso no tratamento de rosácea e método para tratar rosácea para um paciente - Google Patents

composição para uso no tratamento de rosácea e método para tratar rosácea para um paciente Download PDF

Info

Publication number
BR112019024538A2
BR112019024538A2 BR112019024538A BR112019024538A BR112019024538A2 BR 112019024538 A2 BR112019024538 A2 BR 112019024538A2 BR 112019024538 A BR112019024538 A BR 112019024538A BR 112019024538 A BR112019024538 A BR 112019024538A BR 112019024538 A2 BR112019024538 A2 BR 112019024538A2
Authority
BR
Brazil
Prior art keywords
rosacea
patient
treatment
composition
growth factor
Prior art date
Application number
BR112019024538A
Other languages
English (en)
Inventor
Ni Jinsong
Yang Rong
Whitcup Scott
Original Assignee
Ni Jinsong
Yang Rong
Whitcup Scott
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ni Jinsong, Yang Rong, Whitcup Scott filed Critical Ni Jinsong
Publication of BR112019024538A2 publication Critical patent/BR112019024538A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

uma composição para uso no tratamento de rosácea inclui um inibidor multiquinase que inibe tanto um receptor de fator de crescimento endotelial vascular quanto um receptor de fator de crescimento de fibroblasto. um método para tratar rosácea em um paciente inclui inibir um receptor de fator de crescimento endotelial vascular do paciente; e inibir um receptor de fator de crescimento de fibroblasto do paciente.
BR112019024538A 2017-05-26 2018-05-25 composição para uso no tratamento de rosácea e método para tratar rosácea para um paciente BR112019024538A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762511929P 2017-05-26 2017-05-26
PCT/US2018/034583 WO2018218116A1 (en) 2017-05-26 2018-05-25 A topical composition for treating rosacea and a method for treating rosacea with the same

Publications (1)

Publication Number Publication Date
BR112019024538A2 true BR112019024538A2 (pt) 2020-06-09

Family

ID=64396935

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112019024538A BR112019024538A2 (pt) 2017-05-26 2018-05-25 composição para uso no tratamento de rosácea e método para tratar rosácea para um paciente

Country Status (10)

Country Link
US (1) US11179388B2 (pt)
EP (1) EP3630161A4 (pt)
JP (1) JP2020521812A (pt)
KR (1) KR20200010225A (pt)
CN (1) CN110582294A (pt)
AU (1) AU2018272023A1 (pt)
BR (1) BR112019024538A2 (pt)
CA (1) CA3061196A1 (pt)
MX (1) MX2019012892A (pt)
WO (1) WO2018218116A1 (pt)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20190388407A1 (en) * 2017-02-12 2019-12-26 Aiviva Biopharma, Inc. Multikinase inhibitors of vegf and tfg beta and uses thereof
AU2019272871A1 (en) * 2018-05-25 2020-12-03 Ads Therapeutics Llc A composition for treating ocular hyperemia and a method for treating ocular hyperemia with the same
FR3119987B1 (fr) 2021-02-19 2023-01-13 Tarian Pharma Composition hydrogel et ses utilisations dans la prévention et/ou le traitement des dommages cutanés causés par les rayonnements
CN115400123A (zh) * 2021-05-26 2022-11-29 四川科瑞德制药股份有限公司 一种替扎尼定液体制剂及其用途

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140031310A1 (en) * 2011-01-18 2014-01-30 John Maki Pharmaceutical compositions and methods for making and using them
EP2731606A1 (en) * 2011-07-14 2014-05-21 Allergan, Inc. Gel compositions of oxymetazoline and methods of use
US9688688B2 (en) * 2013-02-20 2017-06-27 Kala Pharmaceuticals, Inc. Crystalline forms of 4-((4-((4-fluoro-2-methyl-1H-indol-5-yl)oxy)-6-methoxyquinazolin-7-yl)oxy)-1-(2-oxa-7-azaspiro[3.5]nonan-7-yl)butan-1-one and uses thereof
WO2017053807A2 (en) 2015-09-23 2017-03-30 Genentech, Inc. Optimized variants of anti-vegf antibodies
KR102317700B1 (ko) 2015-10-07 2021-10-26 아이비바 바이오파마, 인크. 피부 섬유성 장애를 치료하는 조성물 및 방법
US20190388407A1 (en) * 2017-02-12 2019-12-26 Aiviva Biopharma, Inc. Multikinase inhibitors of vegf and tfg beta and uses thereof

Also Published As

Publication number Publication date
AU2018272023A1 (en) 2019-11-21
JP2020521812A (ja) 2020-07-27
WO2018218116A1 (en) 2018-11-29
MX2019012892A (es) 2019-12-11
EP3630161A4 (en) 2021-03-03
EP3630161A1 (en) 2020-04-08
CN110582294A (zh) 2019-12-17
US11179388B2 (en) 2021-11-23
CA3061196A1 (en) 2018-11-29
US20200121675A1 (en) 2020-04-23
KR20200010225A (ko) 2020-01-30

Similar Documents

Publication Publication Date Title
BR112019024538A2 (pt) composição para uso no tratamento de rosácea e método para tratar rosácea para um paciente
SG10201908697XA (en) A pharmaceutical composition for use in the treatment or prevention of a c5-related disease and a method for treating or preventing a c5-related disease
CL2019000268A1 (es) Composición de cannabis.
UY35313A (es) Antiadhesion de leucocitos para mitigar los potenciales eventos adversos causados por los dominios de unión específicos de cd3
MX2022001075A (es) Compuestos para usarse en el tratamiento de cancer de mama que expresa el receptor de androgenos (ar+).
UY38403A (es) Moduladores de la alfa-1 antitripsina
ES2692773T3 (es) Tratamientos para la fibrosis
BR112017007144A2 (pt) ácido valproico ou um sal farmaceuticamente aceitável do mesmo, composto, composição farmacêutica, e, composto ou composição para uso, uso, método ou composição.
CO2020015923A2 (es) Antagonista de gremlin-1 para la prevención y tratamiento del cáncer
BR112015026247A2 (pt) métodos para o tratamento de câncer com o uso de terapia combinada com inibidor de cinase tor
CL2012002887A1 (es) Combinación farmacéutica que comprende compuestos derivados de 2,3-dihidroimidazo[1,2-c]quinazolina sustituida, compuestos derivados de n-(2-arilamino)arilsulfonamida y opcionalmente otros agentes farmacéuticos adicionales; kit faramacéutico; método de tratamiento; y su uso para el tratamiento o la profilaxis del cáncer.
CO2021004141A2 (es) Moduladores de la expresión de pnpla3
BR112017006406A2 (pt) composições e métodos para o tratamento e profilaxia de infecções de sítio cirúrgico
MX2021006884A (es) Compuestos y su uso para el tratamiento de la deficiencia de alfa1-antitripsina.
AR112144A1 (es) Compuestos para el tratamiento del sarcoma
BR112016027043A8 (pt) combinação, composição farmacêutica compreendendo glucocorticoide e edo-s101, kit e uso no tratamento de câncer
HRP20240098T1 (hr) Kombinacije fiksnih doza koje sadrže etc1002 i jedan ili više statina za liječenje ili smanjivanje kardiovaskularnih rizika
IL280475A (en) A pharmaceutical composition for use in the treatment or prevention of a C5-related disease and a method for the treatment or prevention of a C5-related disease
EA201890728A3 (ru) Лечение ингибиторами ntcp атеросклероза, первичного билиарного цирроза и заболевания, связанного с nrlp3-инфламмасомами
BR112017016428A2 (pt) ?composto ou sal farmaceuticamente aceitável, composição farmacêutica, uso de um composto ou sal farmaceuticamente aceitável, e, método para tratamento de um distúrbio hiperproliferativo maligno, de uma condição metabólica associada à obesidade, de um distúrbio autoimune ou de um distúrbio inflamatório?
ECSP20082339A (es) Moduladores de la expresión de apol1
IL288010A (en) Antagonists to the complement system for the treatment of paraproteinemic neuropathies
CO2021007006A2 (es) Moduladores de la expresión de irf5
BR112021017550A2 (pt) Métodos de tratamento da amiloidose al
CL2021001136A1 (es) Composiciones y métodos para tratar y prevenir la esclerosis lateral amiotrófica.

Legal Events

Date Code Title Description
B350 Update of information on the portal [chapter 15.35 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 5A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2724 DE 21-03-2023 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.